Portfolio company
Armatus
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops vectorized RNAi therapeutics to treat genetic neurological and neuromuscular diseases for patients with rare conditions.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Shape Therapeutics
The company develops programmable RNA medicines and delivery systems for patients with genetic disorders and other hard-to-treat diseases.
ARTHEx Biotech
This clinical-stage biotechnology company develops RNA-based treatments for patients with rare neuromuscular genetic diseases, including myotonic dystrophy type 1.
Affinia Therapeutics
This company develops rationally designed gene therapies and viral vectors for patients with heart and central nervous system diseases.
Aptadir Therapeutics
The company develops RNA inhibitor-based therapeutics that reactivate silenced genes to treat patients with intractable cancers and rare genetic conditions.
Biorchestra
The company develops RNA-based medicines and delivery systems for patients with neurodegenerative and rare central nervous system diseases.
Typewriter Therapeutics
The company develops RNA-based genetic medicines for patients with cancer, autoimmune conditions and rare genetic diseases.
Anvesana
Anvesana develops therapeutics for patients with rare genetic disorders by leveraging an RNA-sequence analysis platform to identify targets for up-regulating gene expression.
Airna
This company develops RNA editing therapeutics to treat patients with rare genetic and common cardiometabolic diseases.